IL-6作为自免疾病的重要靶点已取得显著成功,全球已有4款靶向IL-6/IL-6R的药物获批上市。首款IL-6R单抗托珠单抗凭借先发优势和多项适应症长期占据市场主导地位,并在2021年因获FDA紧急授权用于重症新冠治疗,销售额达到39.6亿美元峰值。随着托珠单抗专利到期,生物类似药陆续进入市场,竞争加剧。药企纷纷转向差异化布局,拓展IL-6抑制剂在风湿病以外的新适应症。IL-6作为一种多效性...
Source LinkIL-6作为自免疾病的重要靶点已取得显著成功,全球已有4款靶向IL-6/IL-6R的药物获批上市。首款IL-6R单抗托珠单抗凭借先发优势和多项适应症长期占据市场主导地位,并在2021年因获FDA紧急授权用于重症新冠治疗,销售额达到39.6亿美元峰值。随着托珠单抗专利到期,生物类似药陆续进入市场,竞争加剧。药企纷纷转向差异化布局,拓展IL-6抑制剂在风湿病以外的新适应症。IL-6作为一种多效性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.